SUNDAY 9 JULY 2017

7.30 – 8.30  Clinical Trial Updates AUDITORIUM
CMTR Day 1

Chairs: David R. Cornblath and Mary M. Reilly

7.30  Safety And Efficacy of Inotersen in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN)
Teresa Coelho

7.45  The CMT Patient Experience and the Impact of Patient Reported Outcomes on Clinical Research and Trials
Allison Moore

7.55  The Effects of a Novel Exercise and Mobility Program on Clinical, Performance, and Patient Reported Outcome Measures in Patients with CMT
James Nussbaum

8.00  The Effects of a Gravity Supported Exercise Program on Performance, Clinical, and Patient Reported Outcome Measures in Patients with CMT
James Nussbaum

8.05  The German Charcot-Marie-Tooth Disease Network (CMT-NET): Disease Severity and Prognostic Biomarkers from Blood and Skin of CMT1a Patients
Thomas Prukop

8.10  Closing & remarks
Monday 10 July 2017

7.30 – 8.30  Clinical Trial Updates AUDITORIUM CIDP

    Chairs: David R. Cornblath and Mary M. Reilly

7.30      PATH study: Additional results
          Orell Mielke

7.40      Rozanolixizumab: Development of a novel immunomodulator
          Peter Kiessling

7.50      The DRIP study: A dose response trial of IVlg in CIDP
          Krista Kuitwaard

7.55      Safety of IVIG in children with CIDP: the Privigen Post Approval Safety Study
          Amgad Shebl

8.00      Intravenous immunoglobulin in CIDP (IOC trial)
          Filip Eftimov

8.05      Optimal treatment in CIDP (OPTIC trial)
          Filip Eftimov

8.10      INChase CIDP registry: Outcome measures for clinical trials
          Filip Eftimov

8.15      Efficacy and Safety of Three Different Dosages of IVIG (PANZYGA®) in
          Patients with CIDP (ProCID Study): Design of a Phase 3 Study
          David Cornblath

8.20      Issues in Clinical Trials Designs
          Deborah Gelinas

8.25      Closing & remarks
TUESDAY 11 JULY 2017

7.30 – 8.30  Clinical Trial Updates  AUDITORIUM
CMTR Day 2

Chairs: David R. Cornblath and Mary M. Reilly

7.30
Treating Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1) with L-Serine
Vera Fridman

7.40
Aerobic Exercise for Subjects Affected by CMT Neuropathy: Results of a Multicenter, Prospective, Randomized, Single Blind, Controlled Clinical Trial
Angelo Schenone

7.50
A Phase 3 multi-center, randomised, double-blind, placebo controlled trial to assess the efficacy and safety of PXT3003 for CMT1A (PLEO-CMT)
René Goedkoop

7.55
A Phase 2 Study of ACE-083 in Patients with CMT1 or CMTX and Ankle Dorsiflexion Weakness
Kenneth M. Attie

8.00
Characteristics of Recovery from Muscle Fatigue in CMT Patients with Electromyographic Study (Third Report)
Toshinori Shimo

8.05
Announcement of IFB-088 clinical trial for CMT1A patients
Caroline Treins

8.10
Closing & remarks
WEDNESDAY 12 JULY 2017

7.30 – 8.30  Clinical Trial Updates  
GBS and Neuropathy

Chairs: David R. Cornblath and Mary M. Reilly

7.30  
Efficacy and safety of eculizumab in patients with Guillain-Barre syndrome: a randomized, double blind, placebo-control, phase 2 trial (JET-GBS)
Satoshi Kuwabara

7.45  
Complement-related biomarkers in GBS: Analysis of IGOS serum and CSF samples
Ted Yednock

7.55  
Small volume plasma exchange for Guillain-Barré syndrome in low-income countries: a safety and feasibility study
Badrul Islam

8.05  
Second IVIg Dose in Guillain-Barre syndrome patients with poor prognosis; an update.
Christa Walgaard

8.10  
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
Richard J. Barohn

8.15  
Pregabalin for neuropathic pain in Epidermolysis Bullosa
Margarita Calvo

8.20  
Ixazomib, Lenalidomide, and Dexamethasone for Patients with POEMS Syndrome
Michelle Mauermann

8.25  
Closing & remarks